AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tela Bio Exceeds $20M Revenue in Q2 2025, Reiterates $85M-$88M 2025 Target Amid International Expansion
ByAinvest
Monday, Aug 11, 2025 7:08 pm ET1min read
Tela Bio reiterated its 2025 revenue target of $85M-$88M, citing acceleration in international expansion. Q2 2025 saw the first quarter to exceed $20M in revenue, with the highest global unit sales across all products.
TELA Bio, Inc. (TELA) has reiterated its 2025 revenue target of $85 million to $88 million, reflecting acceleration in international expansion. The company reported its second quarter (Q2) 2025 results, with revenue exceeding $20 million for the first time, driven by the highest global unit sales across all products [1].The Q2 2025 revenue increased by 26% year-over-year, reaching $20.2 million. Revenue from OviTex grew by 12%, while OviTex PRS revenue surged by 53%. Gross margin improved to 69.8% from 68.8% in the prior year period. The company ended the quarter with $35 million in cash and cash equivalents [2].
CEO Antony Koblish highlighted the strong performance, stating, "Q2 2025 was the first quarter to exceed $20 million in revenue, stemming from the highest global unit sales in the quarter across all product categories." The company's international sales grew by 25% over Q2 last year, with European sales contributing significantly to this growth [2].
TELA Bio has expanded its European market presence with a new product launch and secured a 4-year framework agreement with the National Health Service (NHS) in England. The company has also appointed Jeff Blizzard as President, who brings extensive European market experience and a track record of delivering predictable growth [2].
The company's focus on enhanced territory management and a patient-centric commercial strategy is expected to drive future growth. TELA Bio aims to achieve its full-year 2025 guidance of $85 million to $88 million, representing a 23% to 27% year-over-year growth [2].
Analysts maintain a neutral to slightly positive tone, with the current average analyst rating on the shares being "buy." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXBE3528:0-tela-bio-misses-q2-revenue-estimates/
[2] https://seekingalpha.com/news/4483591-tela-bio-reiterates-85m-88m-2025-revenue-target-as-international-expansion-accelerates
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet